News

Real-world data demonstrated marked impacts on the economy on a national and personal level.

Nurse practitioners and physician assistants play a crucial role in dermatology, and Dermatology Times is proud to curate content embracing and empowering the NP/PA community.

IL-17A was antagonized by secukinumab, while several other serum levels were decreased in expression.

Answer today's poll below.

Course directors share which pearls, sessions, and insights they are looking forward to this weekend in Asheville, North Carolina.

When sessions conclude, you will find no shortage of opportunities to keep you busy.

A study found that the costs associated with managing comorbidities of hidradenitis suppurativa increase among adults and adolescents.

In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about retinol use.

The American Skin Association estimated that 50 million Americans are exposed to urushiol yearly, the most common contact allergen in the US.

Patients with the rare autosomal recessive genodermatosis are prone to extreme photosensitivity and changes in skin pigmentation.

Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Based on the positive topline phase 3 results, Journey Medical plans to submit a New Drug Application to the FDA in the second half of 2023.

Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.

Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.

Researchers sought to challenge the perception of microneedling as disruptive to the skin and disease states.

Researchers conducted a review of treatments for the rare disease in the pediatric population.

Click here to answer this week's HS poll.

The 2023 Society for Pediatric Dermatology Meeting kicks off in Asheville, North Carolina, on July 13.

Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.

Bush revealed what she is looking forward to in the coming year and the goals she wants to accomplish.

Dupilumab self-injection has been available to patients in Japan since May 2019.

Compared to patients without melasma, blue light irradiation caused minimal changes in patients with melasma.

Click here to answer this week's poll.

Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.

In a clinical trial, patients reported improved quality of life after 12 weeks on sonelokimab.

Findings indicate no rebound effect when participants discontinue dupilumab.

Steven Hacker, MD, explains how the electromagnetic resonant scalpel provides a digitized record of the in vivo scalpel path.

ICYMI, this week we had stories about burn management and treatment in light of the July 4 holiday, pearls from the 2023 World Congress of Dermatology meeting in Singapore, acral lentiginous melanoma in AAPI patients, and more.

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.